Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine

Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludarabine for cyclophosphamide (BuFlu) to reduce...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Harris, Andrew C., Boelens, Jaap J., Ahn, Kwang Woo, Fei, Mingwei, Abraham, Allistair, Artz, Andrew, Dvorak, Christopher, Frangoul, Haydar, Freytes, Cesar, Gale, Robert Peter, Hong, Sanghee, Lazarus, Hillard M., Loren, Alison, Mineishi, Shin, Nishihori, Taiga, O’Brien, Tracey, Williams, Kirsten, Pasquini, Marcelo C., Levine, John E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998928/
https://ncbi.nlm.nih.gov/pubmed/29844205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016956
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi